遺伝性血管性浮腫の青年および成人における血管性浮腫発作のオンデマンド治療のための経口デュクリチバントソフトカプセルの研究

基本情報

NCT ID: NCT06343779
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 134
治験依頼者名: Pharvaris Netherlands B.V.

概要

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.

対象疾患

Hereditary AngioedemaHereditary Angioedema Type IHereditary Angioedema Type IIHereditary Angioedema Types I and IIHereditary Angioedema AttackHereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 1Hereditary Angioedema - Type 2C1 Esterase Inhibitor [C1-INH] DeficiencyC1 Esterase Inhibitor DeficiencyC1 Esterase Inhibitor, Deficiency ofC1 Inhibitor DeficiencyHereditary Angioedema - Type 3Hereditary Angioedema Type III

介入

Deucrictibant, Placebo(DRUG)

依頼者（Sponsor）

Pharvaris Netherlands(INDUSTRY)